CA
FULC icon

Clearstead Advisors’s Fulcrum Therapeutics FULC Stock Holding History

Clearstead Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$198 Buy
+54
New +$328 ﹤0.01% 3205
2025
Q4 		– Sell
-4
Closed -$37 – 2932
2025
Q3 		$37 Buy
+4
New +$29 ﹤0.01% 2995

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Clearstead Advisors's FULC Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Fulcrum Therapeutics (FULC) in Q2 2026: 54 shares worth $198. The stake represents ﹤0.01% of the portfolio and ranks #3205 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in FULC as recently as Q3 2025.

Clearstead Advisors first reported a position in FULC in Q3 2025 and has held it in 2 quarters since. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Clearstead Advisors held 54 shares of Fulcrum Therapeutics worth $198 as of Q2 2026.
  • Fulcrum Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Fulcrum Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3205 holding.
  • Clearstead Advisors first reported a position in Fulcrum Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.